AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03536455
Drug: ACETAZOLAMIDE oral capsule
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m
Trial: NCT01531283
Drug: unacylated ghrelin
RxNorm normalized name: Ghrelin
DrugBank: Lenomorelin (DB11895)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV, UAG (4.0 µg/kg/hr), one time, duration of study visit (approximately 5 hours)
Trial: NCT01531283
Drug: saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV, saline, one time, for the duration of the study visit(approximately 5 hours)
Trial: NCT01490658
Drug: repaglinide
RxNorm normalized name: Repaglinide
DrugBank: Repaglinide (DB00912)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose of 2 mg tablets administered immediately prior to a standard high fat breakfast concomitantly with metformin as separate tablets. Subjects will be randomised to receive trial drug on 3 separate dosing visits in varying order out of 6 possible treatment periods
Trial: NCT01490658
Drug: metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Single dose of 500 mg tablets administered immediately prior to a standard high fat breakfast concomitantly with repaglinide as separate tablets. Subjects will be randomised to receive trial drug on 3 separate dosing visits in varying order out of 6 possible treatment periods
Trial: NCT01490658
Drug: repaglinide and metformin combination tablet
RxNorm normalized name: metformin and repaglinide
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Single dose of 2 mg repaglinide/500 mg metformin (NN4440 2/500) or 1 mg repaglinide/500 mg metformin (NN4440 1/500)administered immediately prior to a standard high fat breakfast. Subjects will be randomised to receive trial drug on 3 separate dosing visits in varying order out of 6 possible treatment periods
Trial: NCT01175785
Drug: fludarabine phosphate
RxNorm normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01175785
Drug: cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01175785
Drug: mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV and PO
Trial: NCT02116010
Drug: Standard of care : Silver Sulfadiazine
DrugBank: Sulfadiazine (DB00359)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Use of Standard of care : Silver Sulfadiazine, to treat E. coli or P. aeruginosa infected burn wound
Trial: NCT02172768
Drug: micafungin
RxNorm normalized name: Micafungin
DrugBank: Micafungin (DB01141)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00221403
Drug: Risperidone oral solution
RxNorm normalized name: Risperidone Oral Solution
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: liquid, BID dosing.
Trial: NCT02600507
Drug: Lumateperone (ITI-007)
RxNorm normalized name: Arthur Itis
DrugBank: Lumateperone (DB06077)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01987297
Drug: ATRA+Arsenic
RxNorm normalized name: ATRA
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ATRA: 25mg/m2 daily；Induction: D1 to CR; Consolidation: D1-14 each course; Maintenance: D1-14 each course.~Arsenic: 0.16mg/kg daily. Induction: D1 to CR; Consolidation: low/intermediate-risk patients 28 days each course; high-risk: 14 days each course; Maintenance: 14 days on and off each course.~Idarubicin 8mg/m2 or Daunorubicin 45mg/m2 daily. Induction: 3-4 days in high-risk patients or intermediated-risk patients with leukocytosis developed during induction therapy. Consolidation: 3 days in high-risk patients in first 2 courses.~MTX: 15mg/m2 qw Maintenance: qw x 4 in each course for high-risk patients.
Trial: NCT01987297
Drug: ATRA+Chemo
RxNorm normalized name: ATRA
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ATRA: 25mg/m2 daily；Induction: D1 to CR; Consolidation: D1-14 each course; Maintenance: D1-14 each course.~Arsenic: 0.16mg/kg daily. Induction: D1 to CR; Maintenance: 14 days on and off each course.~Idarubicin 8mg/m2 or Daunorubicin 45mg/m2 daily. Induction: 3-4 days in high-risk patients or intermediated-risk patients with leukocytosis developed during induction therapy. Consolidation: 3 days in all patients in 2 courses.~Cytarabine: 150mg/m2 or 1g/m2. Consolidation: 150mg/m2 daily x 7 days in high risk patients in first 2 courses; 1g/m2 q12 x 6 doses in third course.~MTX: 15mg/m2 qw Maintenance: qw x4 in each course for high-risk patients.
Trial: NCT00621504
Drug: Ceftaroline fosamil for Injection
RxNorm normalized name: ceftaroline fosamil Injection
DrugBank: Ceftaroline fosamil (DB06590)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 consecutive, 300 mg dose parenteral infused over 30 minutes, every 12 hours, for 5 to 7 days
Trial: NCT00621504
Drug: IV Ceftriaxone
DrugBank: Ceftriaxone (DB01212)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 g dose parenteral infused over 30 minutes, every 24 hours, for 5 to 7 days
Trial: NCT03218787
Drug: DAPT
RxNorm normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-month clear subjects who receive 3-month DAPT without interruption of either aspirin and/or P2Y12 receptor inhibitor for \> 7 consecutive days.~Subject who are 3-month clear will discontinue P2Y12 inhibitor after 3-month visit, but continue taking aspirin through 12-month follow-up. Subjects who are not eligible for early P2Y12 inhibitor discontinuation will be treated per site standard of care.
Trial: NCT00829894
Drug: Risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1 mg Tablet
Trial: NCT02577458
Drug: CM082
RxNorm normalized name: Camostat Mesilate
DrugBank: Camostat (DB13729)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CM082 tablets taken orally once a day on 28-day cycles
Trial: NCT02577458
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus tablets taken orally once a day on 28-day cycles
Trial: NCT01386853
Drug: Pitavastatin
RxNorm normalized name: Pitavastatin
DrugBank: Pitavastatin (DB08860)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 mg QD
Trial: NCT01386853
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg QD
Trial: NCT02292225
Drug: IPI-145 (duvelisib)
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 25mg and/or 5mg oral capsule
Trial: NCT02292225
Drug: Obinutuzumab
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1000mg/40mL single-use vials
Trial: NCT04026997
Drug: CIN-102 Dose 1
RxNorm normalized name: CIN-QUIN
DrugBank: Quinidine (DB00908)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CIN-102 Dose 1
Trial: NCT04026997
Drug: CIN-102 Dose 2
RxNorm normalized name: CIN-QUIN
DrugBank: Quinidine (DB00908)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CIN-102 Dose 2
Trial: NCT04026997
Drug: CIN-102 Dose 3
RxNorm normalized name: CIN-QUIN
DrugBank: Quinidine (DB00908)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CIN-102 Dose 3
Trial: NCT02389361
Drug: Paracetamol-Tramadol
RxNorm normalized name: tramadol and paracetamol
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Postoperative analgesia with intravenous Paracetamol and Tramadol
Trial: NCT03072147
Drug: Teriparatide
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 20 mcg of teriparatide injected in thigh or abdomen once a day for 24 weeks.
Trial: NCT03649763
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: lidocaine 1%, distal ( ulnar and medial nerve): 6ml/nerve , 12m total
Trial: NCT03649763
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.5%,distal ( ulnar and medial nerve): 6ml/nerve , 12m total
Trial: NCT03649763
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: lidocaine 1%, distal and proximal ( ulnar and medial nerve): 3ml/nerve , 12m total
Trial: NCT04584749
Drug: Lidocaine Iv
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2% lidocaine or 0.9% physiological saline will be used as placebo, and it will be administered as a bolus during anesthetic induction equivalent to 1.5 mg / kg of lidocaine. After induction, an intravenous infusion will be started at 0.1 ml / kg / h of the study preparation, equivalent to 2mg / kg / h of lidocaine.~20 ml syringe for induction and two 50 ml syringes for anesthetic maintenance containing 2% Lidocaine .
Trial: NCT01923909
Drug: Intra-articular platelet-rich plasma
RxNorm normalized name: Platelet Rich Plasma
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular platelet-rich plasma This involves withdrawal of 10-15cc of patient's blood, which is collected and centrifuged in Rotofix 32 A Centrifuge machine at 1500 cycles/minute for 5 minutes. 3-4cc of the PRP is obtained and injected into the supra patellar pouch using an aseptic technique. The procedure will be performed by the principal investigator, a qualified consultant Orthopedic surgeon. Analgesia will be administered as needed.
Trial: NCT02452463
Drug: Nintedanib
RxNorm normalized name: Nintedanib
DrugBank: Nintedanib (DB09079)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT01916720
Drug: SB-480848 40 mg
RxNorm normalized name: SB-649868
DrugBank: SB-649868 (DB14822)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study Drug
Trial: NCT01916720
Drug: SB-480848 80 mg
RxNorm normalized name: SB-649868
DrugBank: SB-649868 (DB14822)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study Drug
Trial: NCT02213367
Drug: Bilastine
RxNorm normalized name: bilastine
DrugBank: Bilastine (DB11591)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: 20mg (8 weeks)
Trial: NCT02213367
Drug: Bilastine
RxNorm normalized name: bilastine
DrugBank: Bilastine (DB11591)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: 40mg
Trial: NCT02213367
Drug: Bilastin
RxNorm normalized name: Bilastina
DrugBank: Bilastine (DB11591)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: 80mg
Trial: NCT04437303
Drug: Continuation of oral anticoagulants
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral anticoagulant treatment will not be interrupted before the procedure.
Trial: NCT04437303
Drug: Interruption of oral anticoagulants
RxNorm normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peri-operative interruption of oral anticoagulants will be according to the Dutch guideline on antithrombotic therapy.~* For direct oral anticoagulant users this will be in general 48 hours before the procedure, except for Dabigatran users with renal insufficiency: with estimated glomerular filtration rate 50-80 mL/min/1.73m\^2 72 hours and with estimated glomerular filtration rate 30-50 mL/min/1.73m\^2 96 hours before procedure.~* For vitamin K antagonist users this will be 5 days for phenprocoumon and 3 days for acenocoumarol.~* After the procedure oral anticoagulants will be resumed after 24 hours, if deemed safe by the treating physician.
Trial: NCT04041856
Drug: Povidone Ophthalmic
RxNorm normalized name: povidone ophthalmic
DrugBank: Povidone (DB11061)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Povidone-iodine 2% eye drop versus artificial tear drop for treatment of adenoviral keratoconjunctivitis
Trial: NCT00023530
Drug: fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00023530
Drug: voriconazole
RxNorm normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03505151
Drug: BI 409306 (C-13/N-15)
RxNorm normalized name: SODIUM NITRATE N-15
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: i.v solution
Trial: NCT03505151
Drug: BI 409306
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film-coated tablet
Trial: NCT01780610
Drug: estradiol and progesterone
RxNorm normalized name: ESTRADIOL/PROGESTERONE
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oral estradiol, 2 mg, once daily, was introduced on cycle day 3 with an increasing doses protocol. If the endometrial thickness was greater than 7mm, progesterone 40-60 mg in oil was administered via intramuscular injection. Transfer of thawed embryos was performed 3 days later
Trial: NCT01165450
Drug: Nexagon
RxNorm normalized name: NEXAGON
DrugBank: CODA-001 (DB14915)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: There will be 3 groups of patients with persistent epithelial defects, treated in a dose-escalation fashion from 1µg to 3µg to 10 µg. Each group will consist of 18 patients randomized to Nexagon and 6 patients randomized to placebo only.
Trial: NCT03887884
Drug: CVT-301
RxNorm normalized name: CVT-6883
DrugBank: CVT-6883 (DB05936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levodopa Inhalation Powder
Trial: NCT03887884
Drug: Sinemet
RxNorm normalized name: Sinemet
DrugBank: Carbidopa (DB00190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single oral dose of Carbidopa/Levodopa 25 mg/100 mg
Trial: NCT03363555
Drug: SHR-1210
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A humanized monoclonal immunoglobulin.
Trial: NCT02716311
Drug: Afatinib
RxNorm normalized name: Afatinib
DrugBank: Afatinib (DB08916)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02716311
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00414180
Drug: Bupropion SR
RxNorm normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01554410
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly infusion of 40 mg/m2 x 5 weeks (70 mg maximum)
Trial: NCT01554410
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Weekly infusion x 5 weeks at escalating dose levels (50mg/m2, 75mg/m2, 100mg/m2, and 125mg/m2)
Trial: NCT02220049
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01748344
Drug: Cetirizine
RxNorm normalized name: Cetirizine
DrugBank: Cetirizine (DB00341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10mg tablets
Trial: NCT01704378
Drug: biphasic insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Individually adjusted dose. Injected subcutaneously (s.c., under the skin) twice daily before breakfast and evening meal
Trial: NCT01748344
Drug: High dose ONO-4053
RxNorm normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental
Trial: NCT01748344
Drug: Low dose ONO-4053
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Experimental
Trial: NCT01730846
Drug: Doxazosin 4mg/day
DrugBank: Doxazosin (DB00590)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4 mg/day with 3-week lead-in medication period. Maintained at steady state for duration of the study. 5-day taper at the end of the study.
Trial: NCT01730846
Drug: Doxazosin 8mg/day
DrugBank: Doxazosin (DB00590)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8 mg/day with 3-week lead-in medication period. Maintained at steady state for duration of the study. 5-day taper at the end of the study.
Trial: NCT01296607
Drug: Urocortin 2
RxNorm normalized name: Urocortin 2
DrugBank: Urocortin-2 (DB13033)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol 4a: Onset/Offset protocol: (Visits 1 or 3)~Following a 20-minute period of saline infusion for equilibration of the set-up, subjects will receive incremental doses of Urocortin 2 in the presence of a saline washout between each dose.~Urocortin 2 will be infused at 3.6, 12, 36 and 120 pmol/min (15, 50, 150 and 498 nanograms/min) to achieve estimated end-organ concentrations of 0.6, 2, 6 and 20 micrograms/L respectively.~Protocol 4b: Reproducibility protocol (Visit 2 or 4)~Following a 20-minute period of saline infusion for equilibration of the set-up, subjects will receive ascending doses of urocortin 2 in the absence of saline washout between each dose. This protocol aims to assess the reproducibility of the vasodilatory effect of urocortin 2 on repeated dosing. The doses used for this protocol will be identical to Protocol a.
Trial: NCT01296607
Drug: Urocortin 3
RxNorm normalized name: Urocortin 2
DrugBank: Urocortin-2 (DB13033)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protocol 4a: Onset/ Offset protocol: (Visit 1 or 3)~Following a 20-minute period of saline infusion for equilibration of the set-up, subjects will receive incremental doses of Urocortin 2 or Urocortin 3 in the presence of a saline washout between each dose.~Urocortin 3 will be infused at 1200, 3600, 12000 and 36000 pmol/min (5, 15, 50 and 150 micrograms/min) to achieve estimated end organ concentrations of 199, 600, 2000 and 6000 micrograms/L respectively.~Protocol 4b: Reproducibility protocol (Visit 2 or 4)~Following a 20-minute period of saline infusion for equilibration of the set-up, subjects will receive ascending doses of urocortin 3 in the absence of saline washout between each dose. This protocol aims to assess the reproducibility of the vasodilatory effect of 3 on repeated dosing. The doses used for this protocol will be identical to Protocol a.
Trial: NCT04454307
Drug: Tramadol
RxNorm normalized name: Tramadol
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: tramadol 100 mg twice daily for 10 days
Trial: NCT03336580
Drug: PRX004
RxNorm normalized name: Immunoglobulin G1, anti-(human transthyretin) (human-Mus musculus monoclonal PRX004 γ1-chain), disulfide with human-Mus musculus monoclonal PRX004 κ-chain, dimer
DrugBank: Coramitug (DB19411)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PRX004 (0.1, 0.3, 1, 3, 10, and 30 mg/kg) IV every 28 days~PRX004 IV every 28 days at RP2D(s)~PRX004 IV every 28 days at RP2D(s)
Trial: NCT03809052
Drug: GB1211
RxNorm normalized name: GB1211
DrugBank: GB1211 (DB17499)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hard capsules for oral use
Trial: NCT00705198
Drug: Temozolomide (for newly diagnosed malignant glioma)
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Temozolomide treatment for newly diagnosed malignant glioma. The usual dose for adults in combination with radiotherapy is 75 mg/m2 orally once daily for 42 consecutive days. After a 4 week rest period, monotherapy at 150 mg/m2 orally once daily for 5 consecutive days per 28 day treatment cycle is administered. The dose may be increased to 200 mg/m2 for the next 28 day treatment cycle.~Temozolomide is administered as 20 mg and 100 mg capsules.
Trial: NCT01950234
Drug: ACTH
RxNorm normalized name: ACTH
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acthar gel
Trial: NCT02584608
Drug: ACTIMMUNE
RxNorm normalized name: Actimmune
DrugBank: Interferon gamma-1b (DB00033)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00004398
Drug: heme arginate
RxNorm normalized name: Heme arginate
DrugBank: Heme arginate (DB17310)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00004398
Drug: tin mesoporphyrin
RxNorm normalized name: Tin mesoporphyrin
DrugBank: Stannsoporfin (DB04912)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01473173
Drug: CJ-12420
RxNorm normalized name: CJ-12420
DrugBank: Tegoprazan (DB16690)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01473173
Drug: Esomeprazole 40mg
RxNorm normalized name: esomeprazole 40 MG
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02082808
Drug: DTG
RxNorm normalized name: Dolutegravir
DrugBank: Dolutegravir (DB08930)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: DTG is provided as 9 millimetre white, film-coated, round tablets debossed with SV 572 on one side and 50 on the other side
Trial: NCT02082808
Drug: DCV
RxNorm normalized name: DCV
DrugBank: AV-COVID-19 (DB15802)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DCV is provided as a plain, green, biconvex, pentagonal film-coated tablet
Trial: NCT00091910
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02496949
Drug: Icaritin
RxNorm normalized name: Icaritin
DrugBank: Icaritin (DB12672)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600mg,800mg two doses, Bid, continuous dosing for 56 days, to assess the safety,tolerance,pharmacokinetics and efficacy of icaritin
Trial: NCT01018862
Drug: Azelastine hydrochloride nasal spray 0.15%
DrugBank: Azelastine (DB00972)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 822 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks
Trial: NCT01018862
Drug: Azelastine hydrochloride nasal spray 0.10%
DrugBank: Azelastine (DB00972)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 548 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks